Brown Deborah Margaret 4
4 · ONCOLYTICS BIOTECH INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Oncolytics (ONCY) Director Deborah Brown Buys 25,000 Shares
What Happened Deborah Margaret Brown, a director of Oncolytics Biotech Inc. (ONCY), acquired 25,000 shares on February 12, 2026 in an open-market purchase (transaction code P). The filing reports a total purchase value of $21,240 (weighted average price ≈ $0.8496, reported as $0.85). This was a direct purchase rather than a grant, exercise, or gift.
Key Details
- Transaction date: 2026-02-12 (filed with the SEC on 2026-02-13 — timely).
- Price: weighted average ≈ $0.8496 per share (reported as $0.85); reported price range for individual trades was $0.835 to $0.85 (see footnote).
- Shares acquired: 25,000; total reported cost: $21,240.
- Shares owned after transaction: not disclosed in the provided filing.
- Footnote: The reported price is a weighted average; the reporting person will provide a breakdown of shares purchased at each price within the $0.835–$0.85 range upon request.
- Transaction type: Open-market purchase (P). No 10b5-1 plan, tax withholding, or option exercise was reported.
Context This was an outright open-market purchase (not an exercise or award). The purchase amount (~$21.2k) is modest in size and, while insider purchases can be viewed positively by investors, they do not prove future company performance.
Insider Transaction Report
Form 4
Brown Deborah Margaret
Director
Transactions
- Purchase
Common Shares
[F1]2026-02-12$0.85/sh+25,000$21,240→ 109,851 total
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.835 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Signature
/s/ Kirk Look, Attorney-in-Fact|2026-02-13